• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Galecto Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/20/25 7:00:15 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GLTO alert in real time by email
    8-K
    false000180031500018003152025-06-182025-06-180001800315dei:FormerAddressMember2025-06-182025-06-18

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 18, 2025

    GALECTO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    001-39655

    37-1957007

    (State or other jurisdiction

    of incorporation)

    (Commission

    File Number)

    (I.R.S. Employer

    Identification No.)

     

    75 State Street, Suite 100

    Boston, MA 02109

    (Address of principal executive offices, including zip code)

    (+45) 70 70 52 10

    (Registrant’s telephone number, including area code)

    Ole Maaloes Vej 3

    DK-2200 Copenhagen N

    Denmark

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class

    Trade

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, $0.00001 par value per share

    GLTO

    The Nasdaq Capital Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


     

    Item 5.07 – Submission of Matters to a Vote of Security Holders.

    Galecto, Inc. (the “Company”) held its annual meeting (the “Annual Meeting”) of stockholders on June 18, 2025. The following proposals were submitted to the stockholders at the Annual Meeting:

    (i)
    To elect Carl Goldfischer, M.D. and David Shapiro, M.D. as Class II members of the Board of Directors, to serve until the Company’s 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified, or until their earlier death, resignation or removal;
    (ii)
    To approve, in accordance with Nasdaq Listing Rule 5635(a), the issuance of shares of common stock upon conversion of the Series A non-voting convertible preferred stock issued to Bridge Medicines LLC on October 7, 2024 (the "Preferred Stock Conversion"); and
    (iii)
    To ratify the selection of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    The proposals are described in detail in the Company’s Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 30, 2025.

    The number of shares of common stock entitled to vote at the Annual Meeting was 1,322,359. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 677,821. All matters submitted to a vote of the Company’s stockholders at the Annual Meeting were approved and all director nominees were elected.

    The number of votes cast for and against and the number of abstentions and broker non-votes with respect to each matter voted upon are set forth below:

    (a)
    Election of Class II Directors.

    Director Nominee

    Votes For

    Votes Withheld

    Carl Goldfischer, M.D.

     

    219,253

     

    23,053

    David Shapiro, M.D.

    226,360

    15,946

     

    There were 435,515 broker non-votes regarding the election of directors.

    (b)
    Preferred Stock Conversion.

     

    Stockholders approved the Preferred Stock Conversion proposal. The results of the voting included 226,407 votes for, 15,099 votes against and 800 votes abstained. There were 435,515 broker non-votes for this proposal.

     

    (c)
    Ratification of the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025.

    Stockholders ratified the appointment of EY Godkendt Revisionspartnerselskab as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025. The results of the voting included 660,974 votes for, 16,319 votes against and 528 votes abstained. There were no broker non-votes regarding this proposal.

     

     

     

     

     


     

    SIGNATURE

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

     

     

     

     

     

     

    Galecto, Inc.

     

     

     

     

    Date: June 20, 2025

     

    By:

    /s/ Hans T. Schambye

     

     

     

    Hans T. Schambye, M.D., Ph.D.

     

     

     

    President and Chief Executive Officer

     

     


    Get the next $GLTO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GLTO

    DatePrice TargetRatingAnalyst
    2/17/2026$45.00Buy
    UBS
    1/7/2026$46.00Outperform
    Leerink Partners
    12/1/2025$32.00Buy
    Guggenheim
    8/6/2021$12.00 → $7.00Outperform
    Credit Suisse
    More analyst ratings

    $GLTO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Galecto with a new price target

    UBS initiated coverage of Galecto with a rating of Buy and set a new price target of $45.00

    2/17/26 8:59:23 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leerink Partners initiated coverage on Galecto with a new price target

    Leerink Partners initiated coverage of Galecto with a rating of Outperform and set a new price target of $46.00

    1/7/26 8:34:02 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Galecto with a new price target

    Guggenheim initiated coverage of Galecto with a rating of Buy and set a new price target of $32.00

    12/1/25 8:28:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Galecto Inc.

    SCHEDULE 13G - Galecto, Inc. (0001800315) (Subject)

    2/17/26 7:17:39 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Galecto Inc.

    SCHEDULE 13D/A - Galecto, Inc. (0001800315) (Subject)

    2/11/26 6:11:02 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Galecto Inc.

    8-K - Galecto, Inc. (0001800315) (Filer)

    2/11/26 5:10:21 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bruno Julianne converted options into 129,000 shares, increasing direct ownership by 1,606% to 137,032 units (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    2/12/26 6:05:08 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Fairmount Funds Management Llc converted options into 8,713,000 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    2/12/26 6:03:41 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Operating Officer Sattarzadeh Sherwin was granted 190,376 shares (SEC Form 4)

    4 - Galecto, Inc. (0001800315) (Issuer)

    1/26/26 9:04:44 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Galecto Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.3 Million

    BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the closing of its previously announced underwritten public offering of 16,644,737 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 2,171,052 additional shares, at a public offering price of $19.00 per share. The aggregate gross proceeds to Galecto from the offering were approximately $316.3 million, before deducting underwriting discounts and commissions and offering expenses payable by Galecto. Jefferies, Leer

    2/12/26 4:01:00 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Pricing of $275 Million Underwritten Public Offering

    BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced the pricing of its previously announced underwritten public offering of shares of its common stock. Galecto is selling a total of 14,473,685 shares of common stock at a public offering price of $19.00 per share. In addition, Galecto has granted the underwriters a 30-day option to purchase an additional 2,171,052 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds to Galecto from the offering are expec

    2/10/26 10:42:03 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock

    BOSTON, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a biopharmaceutical company focused on developing novel therapeutics to redefine the treatment paradigm for people living with blood cancers, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors that so choose, Series C non-voting convertible preferred stock. All of the securities are being offered by Galecto. In addition, Galecto intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. Each share of Series C preferred stock will be convertible into 1,000 shares of common stock at

    2/10/26 4:04:47 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    11/7/24 3:07:49 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Galecto Inc.

    SC 13G - Galecto, Inc. (0001800315) (Subject)

    11/7/24 2:55:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Galecto Inc.

    SC 13G/A - Galecto, Inc. (0001800315) (Subject)

    8/29/24 5:59:56 PM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Leadership Updates

    Live Leadership Updates

    View All

    Galecto Highlights Key Strategic Priorities and Anticipated 2026 Milestones

    DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for expected IND submission, or equivalent, in mid-2026 with anticipated first-in-human dosing via subcutaneous administrationRecent addition of deep hematology/oncology drug development experience with the appointment of a Chief Operating Officer and Chief Medical OfficerPipeline of additional candidates advancing to the clinic, with first IND submission of DMR-002 expected in second half of 2026Cash balance, following $285M raised in the November PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 an

    1/12/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Announces Key Additions to Leadership Team

    Deep hematology/oncology drug development experience added with the appointment of Sherwin Sattarzadeh as Chief Operating Officer and Becker Hewes as Chief Medical Officer DMR-001, a potentially best-in-class mutant calreticulin ("mutCALR") targeting monoclonal antibody, on track for IND submission in mid-2026 with anticipated first-in-human dosing via subcutaneous administration Cash balance, including $285 million raised in November 2025 PIPE, provides financial runway into 2029 to support multiple data milestones, including Ph1 clinical proof-of-concept data for DMR-001 anticipated in 2027 BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Galecto, Inc. ("Galecto" or the "Company"), a biotech

    1/6/26 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler

    BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr. Wechsler brings a unique combination of expertise and a proven track record of leadership in the healthcare industry. "We are thrilled to welcome Dr. Wechsler to our Board of Directors," said Dr. Carl Goldfischer, Chair of the Board of Galecto. "Amy is a distinguished physician who has board certification in both dermatology and psychiatry. Her experience guiding companies through critical growth stages make her an important add

    10/15/24 8:30:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GLTO
    Financials

    Live finance-specific insights

    View All

    Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines

    Galecto will focus on cancer and liver disease, leveraging existing clinical stage asset GB1211Bolsters pipeline by obtaining global rights to BRM-1420, a novel dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of acute myeloid leukemia (AML)BRM-1420 has the potential for enhanced clinical effectiveness compared to FLT3 inhibitors alone and has shown synergistic effects with SOC in preclinical models BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to f

    10/7/24 8:45:46 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto Presents Positive Clinical Data at AASLD Showing Statistically Significant Improvements in Important Liver Parameters in Decompensated Cirrhosis Patients

    Statistically significant reductions observed in ALT, AST and GGT, supporting further development of GB1211 in severe liver diseasesFindings to be discussed in a conference call and virtual webinar today, November 8, 2022, at 8 a.m. ET BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, announced it will discuss topline data and additional analyses from its recently completed Phase 1b/2a GULLIVER-2 trial (NCT05009680), including the observed statistically significant signs of liver protection, in a conference call and virt

    11/8/22 6:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD's The Liver Meeting® 2022

    Late-breaking oral and poster presentations include clinical and preclinical data related to GULLIVER-2 clinical trialGalecto to host a webinar at 8:00 a.m. ET on Tuesday, November 8, 2022 to discuss expanded topline data and analysis BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ:GLTO), a clinical-stage biotechnology company and a world leader in galectin biology focused on the development of novel treatments for fibrosis and cancer, today announced it will present data from its recently completed Phase 1b/2a GULLIVER-2 trial at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting 2022 being held in Washington, D.C. on November 4-8, 2022. G

    10/31/22 8:00:00 AM ET
    $GLTO
    Biotechnology: Pharmaceutical Preparations
    Health Care